Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031

British Journal of Pharmacology

Volumn 144, Issue 1, 2005, Pages 133-143

  Ishikawa, Takeshi ^a   Nishigaki, Fusako ^a   Miyata, Susumu ^a   Hirayama, Yoshitaka ^a   Minoura, Kjoko ^a   Imanishi, Junko ^a   Neya, Masahiro ^a   Mizutani, Tsuyoshi ^a   Imamura, Yoshimasa ^a   Naritomi, Yoichi ^a   Murai, Hidetsugu ^a   Ohkubo, Yoshitaka ^a   Kagayama, Akira ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Collagen induced arthritis; Collagenase; Gelatinase; Matrix metalloproteinase inhibitor; Pharmacokinetics

Indexed keywords

2 [7 [5 (4 ETHYLPHENYL) 2 THIENYL] 1,1 DIOXIDO 4 (2 PYRIDINYLCARBONYL)HEXAHYDRO 1,4 THIAZEPIN 7 YL] N HYDROXYACETAMIDE; ANTIBODY; CIPEMASTAT; COLLAGEN; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ANTIBODY; COLLAGENASE 3; COLLAGENASE INHIBITOR; FR 255031; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; JOINT DESTRUCTION; NONHUMAN; PANNUS; PAW EDEMA; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION; X RAY ANALYSIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EDEMA; FEMALE; HINDLIMB; HUMANS; INFLAMMATION; JOINT DISEASES; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; RATS; RATS, INBRED LEW; THIAZEPINES;

EID: 19944432267     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706054     Document Type: Article

References (47)

1. BEMELMANS, M.H., GOUMA, D.J. & BUURMAN, W.A. (1994). Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine, 6, 608-615.
2. BREWSTER, M., LEWIS, E.J., WILSON, K.L., GREENHAM, A.K. & BOTTOMLEY, K.M. (1998). Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ ORT mouse model of osteoarthritis. Arthritis Rheum., 41, 1639-1644.
3. BRINCKERHOFF, C.E. (1991). Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum., 34, 1073-1075.
4. CAWSTON, T.E. & ROWAN, A. (1998). Prevention of cartilage breakdown by matrix metalloproteinase inhibition - a realistic therapeutic target? Br. J. Rheumatol., 37, 353-356.
5. CLOSE, D.R. (2001). Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis., 60, iii62-67.
6. COURTENAY, J.S., DALLMAN, M.J., DAYAN, A.D., MARTIN, A. & MOSEDALE, B. (1980). Immunisation against heterologous type II collagen induces arthritis in mice. Nature, 283, 666-668.
7. CURRAN, S. & MURRAY, G.I. (1999). Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol., 189, 300-308.
8. DELAISSE, J.M., ENGSIG, M.T., EVERTS, V., DEL CARMEN OVEJERO, M., FERRERAS, M., LUND, L., VU, T.H., WERB, Z., WINDING, B., LOCHTER, A., KARSDAL, M.A., TROEN, T., KIRKEGAARD, T., LENHARD, T., HEEGAARD, A.M., NEFF, L., BARON, R. & FOGED, N.T. (2000). Proteinases in bone resorption: obvious and less obvious roles. Clin. Chim. Acta, 291, 223-234.
9. DODGE, G.R. & POOLE, A.R. (1989). Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J. Clin. Invest., 83, 647-661.
10. ELLERIN, T., RUBIN, R.H. & WEINBLATT, M.E. (2003). Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum., 48, 3013-3022.
11. FINI, M.E., PARKS, W.C., RINEHART, W.B., GIRARD, M.T., MATSUBARA, M., COOK, J.R., WEST-MAYS, J.A., SADOW, P.M., BURGESON, R.E., JEFFREY, J.J., RAIZMAN, M.B., KRUEGER, R.R. & ZIESKE, J.D. (1996). Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am. J. Pathol., 149, 1287-1302.
12. FOSANG, A.J., LAST, K. & MACIEWICZ, R.A. (1996). Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J. Clin. Invest., 98, 2292-2299.
13. HAMADA, T., ARIMA, N., SHINDO, M., SUGAMA, K. & SASAGURI, Y. (2000). Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase- inhibitor. Br. J. Pharmacol., 131, 1513-1520.
14. HART, B.A., BANK, R.A., DE ROOS, J.A., BROK, H., JONKER, M., THEUNS, H.M., HAKIMI, J. & TE KOPPELE, J.M. (1998). Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br. J. Rheumatol., 37, 314-323.
15. HASHIDA, R., KUWADA, M., CHIBA, K.I., HORIZOE, T., SHIROTA, H. & NAGAI, Y. (1996). A factor derived from polymorphonuclear leukocytes enhances interleukin-1-induced synovial cell collagenase and prostaglandin E2 production in rats. Eur. J. Biochem., 236, 517-522.
16. HEROUY, Y., TREFZER, D., ZIMPFER, U., SCHOPF, E., WANSCHEIDT, W. & NORGAUER, J. (2000). Matrix metalloproteinases and venous leg ulceration. Eur. J. Dermatol., 10, 173-180.
17. HOLMBECK, K., BIANCO, P., YAMADA, S. & BIRKEDAL-HANSEN, H. (2004). MT1-MMP: a tethered collagenase. J. Cell. Physiol., 200, 11-19.
18. ITOH, T., TANIOKA, M., YOSHIDA, H., YOSHIOKA, T., NISHIMOTO, H. & ITOHARA, S. (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58, 1048-1051.
19. JACKSON, C., NGUYEN, M., ARKELL, J. & SAMBROOK, P. (2001). Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - targetting gelatinase A activation. Inflamm. Res., 50, 183-186.
20. JOE, B. & WILDER, R.L. (1999). Animal models of rheumatoid arthritis. Mol. Med. Today, 5, 367-369.
21. JONES, C.B., SANE, D.C. & HERRINGTON, D.M. (2003). Matrix metalloproteinases. A review of their structure and role in acute coronary syndrome. Cardiovasc. Res., 59, 812-823.
22. KALDEN, J.R. (2001). How do the biologics fit into the current DMARD armamentarium? J. Rheumatol. Suppl., 62, 27-35.
23. KOIVUNEN, E., ARAP, W., VALTANEN, H., RAINISALO, A., MEDINA, O.P., HEIKKILA, P., KANTOR, C., GAHMBERG, G.G., SALO, T., KONTTINEN, Y.T., SORSA, T., RUOSLAHTI, E. & PASQUALINI, R. (1999). Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 17, 768-774.
24. LARK, M.W., BAYNE, E.K., FLANAGAN, J., HARPER, C.F., HOERRNER, L.A., HUTCHINSON, N.I., SINGER, II, DONATELLI, S.A., WEIDNER, J.R., WILLIAMS, H.R., MUMFORD, R.A. & LOHMANDER, L.S. (1997). Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J. Clin. Invest., 100, 93-106.
25. LEWIS, E.J., BISHOP, J., BOTTOMLEY, K.M., BRADSHAW, D., BREWSTER, M., BROADHURST, M.J., BROWN, P.A., BUDD, J.M., ELLIOTT, L., GREENHAM, A.K., JOHNSON, W.H., NIXON, J.S., ROSE, F., SUTTON, B. & WILSON, K. (1997). Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol., 121, 540-546.
26. LIPSKY, P.E. & KAVANAUGH, A. (1999). The impact of pharmacoeconomic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology (Oxford), 38, 41-44.
27. LUBBERTS, E., JOOSTEN, L.A., CHABAUD, M., VAN DEN BERSSELAAR, L., OPFERS, B., COENEN-DE ROO, C.J., RICHARDS, C.D., MIOSSEC, P. & VAN DEN BERG, W.B. (2000). IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest., 105, 1697-1710.
28. MENGSHOL, J.A., MIX, K.S. & BRINCKERHOFF, C.E. (2002). Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum., 46, 13-20.
29. MILLER, J.A., LIU, R.Q., DAVIS, G.L., PRATTA, M.A., TRZASKOS, J.M. & COPELAND, R.A. (2003). A microplate assay specific for the enzyme aggrecanase. Anal. Biochem., 314, 260-265.
30. MUDGETT, J.S., HUTCHINSON, N.I., CHARTRAIN, N.A., FORSYTH, A.J., MCDONNELL, J., SINGER, II, BAYNE, E.K., FLANAGAN, J., KAWKA, D., SHEN, C.F., STEVENS, K., CHEN, H., TRUMBAUER, M. & VISCO, D.M. (1998). Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum., 41, 110-121.
31. OHUCHI, E., IMAI, K., FUJII, Y., SATO, H., SEIKI, M. & OKADA, Y. (1997). Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem., 272, 2446-2451.
32. POOLE, A.R., KOJIMA, T., YASUDA, T., MWALE, F., KOBAYASHI, M. & LAVERTY, S. (2001). Composition and structure of articular cartilage: a template for tissue repair. Clin. Orthop., 391 (Suppl), S26-S33.
33. POOLE, A.R., PIDOUX, I., REINER, A. & ROSENBERG, L. (1982). An immunoelectron microscope study of the organization of proteoglycan monomer, link protein, and collagen in the matrix of articular cartilage. J. Cell Biol., 93, 921-937.
34. PRATTA, M.A., YAO, W., DECICCO, C., TORTORELLA, M.D., LIU, R.Q., COPELAND, R.A., MAGOLDA, R., NEWTON, R.C., TRZASKOS, J.M. & ARNER, E.C. (2003). Aggrecan protects cartilage collagen from proteolytic cleavage. J. Biol. Chem., 278, 45539-45545 Epub 2003 Jul 30.
35. PRICE, J.S., CHAMBERS, M.G., POOLE, A.R., FRADIN, A. & MASON, R.M. (2002). Comparison of collagenase-cleaved articular cartilage collagen in mice in the naturally occurring STR/ORT model of osteoarthritis and in collagen-induced arthritis. Osteoarthr Cartilage, 10, 172-179.
36. SANG, Q.X. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Res., 8, 171-177.
37. SINGER, I.I., KAWKA, D.W., BAYNE, E.K., DONATELLI, S.A., WEIDNER, J.R., WILLIAMS, H.R., AYALA, J.M., MUMFORD, R.A., LARK, M.W., GLANT, T.T., NABOZNY, G.H. & DAVID, C.H. (1995). VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J. Clin. Invest., 95, 2178-2186.
38. SINGER, I.I., SCOTT, S., KAWKA, D.W., BAYNE, E.K., WEIDNER, J.R., WILLIAMS, H.R., MUMFORD, R.A., LARK, M.W., MCDONNELL, J., CHRISTEN, A.J., MOORE, V.L., MUDGETT, J.S. & VISCO, D.M. (1997). Aggrecanase and metalloproteinase-specific aggrecan neoepitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthr Cartilage, 5, 407-418.
39. STAMENKOVIC, I. (2003). Extracellular matrix remodelling; the role of matrix metalloproteinases. J. Pathol., 200, 448-464.
40. STRONGIN, A.Y., COLLIER, I., BANNIKOV, G., MARMER, B.L., GRANT, G.A. & GOLDBERG, G.I. (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem., 270, 5331-5338.
41. STUART, J.M., CREMER, M.A., KANG, A.M. & TOWNES, A.S. (1979). Collagen-induced arthritis in rats. Evaluation of early immunologic events. Arthritis Rheum., 22, 1344-1351.
42. TRENTHAM, D.E. (1982). Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum., 25, 911-916.
43. TRENTHAM, D.E., TOWNES, A.S. & KANG, A.H. (1977). Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med., 146, 857-868.
44. VAN MEURS, J.B., VAN LENT, P.L., HOLTHUYSEN, A.E., SINGER, II, BAYNE, E.K. & VAN DEN BERG, W.B. (1999). Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum., 42, 1128-1139.
45. VINCENTI, M.P., CLARK, I.M. & BRINCKERHOFF, C.E. (1994). Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum., 37, 1115-1126.
46. YAMANISHI, Y., BOYLE, D.L., CLARK, M., MAKI, R.A., TORTORELLA, M.D., ARNER, E.G. & FIRESTEIN, G.S. (2002). Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J. Immunol., 168, 1405-1412.
47. YU, Q. & STAMENKOVIC, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 14, 163-176.